Ernexa director holds 8K shares, 8K-share warrant
Ernexa Therapeutics Inc. (ERNA) reported the initial equity holdings of director David Polinsky.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Ernexa Therapeutics Inc. (ERNA) reported the initial equity holdings of director David Polinsky. He indirectly holds a warrant, through Polo3K, LLC, to purchase 8,000 shares of Common Stock at an exercise price of $17.00 per share, and indirectly holds 8,000 shares of Common Stock.
The warrant is scheduled to expire on February 10, 2031, but will instead expire earlier if triggered by clinical milestones: specifically, on the 180th calendar day following public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Polinsky David
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrant F1 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Warrant — 8,000 contracts (Indirect, Through Polo3K, LLC);
Common Stock — 8,000 shares (Indirect, Through Polo3K, LLC)
Footnotes (1)
- F1. The warrant will expire on the earlier of (i) the five (5)-year anniversary of the original issuance date or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.
Key Figures
Underlying shares for warrant: 8,000 shares of Common Stock
Warrant exercise price: $17.0000 per share
Warrant scheduled expiration date: 2031-02-10
+1 more
4 metrics
Underlying shares for warrant
8,000 shares of Common Stock
Underlying security shares for the reported warrant position held indirectly
Warrant exercise price
$17.0000 per share
Exercise price for the warrant on Ernexa Therapeutics Inc. Common Stock
Warrant scheduled expiration date
2031-02-10
Five-year anniversary of original issuance date, subject to earlier clinical-data trigger
Indirectly held Common Stock
8,000 shares
Indirect Common Stock holdings through Polo3K, LLC following the reported holdings
Key Terms
Warrant, underlying security, Phase 1 study, clinical trial data
4 terms
Warrant financial
"The warrant will expire on the earlier of (i) the five (5)-year"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.
underlying security financial
"underlying security shares of 8,000.0000 Common Stock"
Phase 1 study medical
"the first cohort of the Phase 1 study of ERNA-101"
A phase 1 study is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, side effects and the right dose rather than proving effectiveness. Think of it as a short, closely monitored test drive that checks how the body tolerates the treatment and how it behaves inside the body; results matter to investors because positive safety and dosing data are needed before larger, more value-driving trials can begin.
clinical trial data medical
"following the public release by the Company of clinical trial data"
Clinical trial data are the collected results from organized studies that test a medical product, procedure or treatment in people, showing how well it works and what side effects occur. For investors, this information is like a detailed test drive report: strong, clear results increase the chance of regulatory approval and commercial success, while negative or mixed data raise development risk, potential delays and uncertainty about future revenue.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is the reporting person in Ernexa Therapeutics Inc. (ERNA)'s Form 3?
The reporting person is David Polinsky, who is identified as a director of Ernexa Therapeutics Inc. The Form 3 reports his initial beneficial ownership in the company’s securities, held indirectly through an entity named Polo3K, LLC.
What warrant position in ERNA does David Polinsky report on Form 3?
He reports an indirect warrant position, through Polo3K, LLC, covering 8,000 underlying shares of Common Stock of Ernexa Therapeutics Inc. The warrant has an exercise price of $17.00 per share.
What is the exercise price of the warrant reported for ERNA?
The warrant reported by David Polinsky, held indirectly through Polo3K, LLC, has an exercise price of $17.00 per share for 8,000 underlying shares of Common Stock of Ernexa Therapeutics Inc.
When does the ERNA warrant held by Polo3K, LLC expire?
The warrant will expire on the earlier of February 10, 2031 (the five-year anniversary of the original issuance date) or the 180th calendar day following the public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.
Is David Polinsky’s ownership in ERNA direct or indirect?
All reported holdings on this Form 3 are indirect. Both the warrant (covering 8,000 underlying shares) and the 8,000 shares of Common Stock are held through Polo3K, LLC, as indicated in the nature of ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.
